Latest news articles

Added 20 days ago Drug news

EMA approves accelerated process of assessment for GSK 2857916 in relapsed or refractory multiple myeloma.- GlaxoSmithKline

GlaxoSmithKline announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for GSK 2857916 (belantamab mafodotin) for...

Added 1 month ago Drug news

FDA grants priority review to GSK 2857916 in relapsed or refractory multiple myeloma.- GlaxoSmithKline

GlaxoSmithKline plc announced the FDA has granted a priority review for the company's Biologics License Application (BLA) seeking approval of...

Added 1 month ago Drug news

EU approves Darzalex + Velcade + Thalomid + dexamethasone in newly diagnosed multiple myeloma.- Genmab

Genmab announced that the European Commission (EC) has granted marketing authorization for Darzalex (daratumumab) in combination with Velcade (bortezomib), Thalomid(thalidomide)...

Search all news articles for Multiple myeloma
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Guidelines

Myeloma: diagnosis and management

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over.

Added 4 years ago

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and...

Added 3 years ago

Guidelines for the use of imaging in the management of patients with myeloma

The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...

Added 1 year ago

Search all guidelines for Multiple myeloma
 

Journal articles

Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.

Background: Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT...

Added 10 months ago

Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.

Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM)...

Added 10 months ago

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

This article summarizes the scientific review of the application leading to regulatory approval in the European Union.

Added 1 year ago

Search all journal articles for Multiple myeloma
 

Clinical trials

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Added 1 year ago

Study of lenalidomide and dexamethasone with or without pembrolizumab (MK-3475) in participants with newly diagnosed treatment naive multiple myeloma (MK-3475-185/KEYNOTE-185)

The purpose of this study is to compare the efficacy of adding pembrolizumab to lenalidomide and low dose dexamethasone in participants with treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (auto-SCT).

Added 2 years ago

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

The purpose of this study is to compare the efficacy of adding pembrolizumab to pomalidomide and low dose dexamethasone in participants with refractory or relapsed multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.

Added 2 years ago

Search all clinical trials for Multiple myeloma